Zu-Chian Chiang | Biochemistry | Best Researcher Award

Dr. Zu-Chian Chiang | Biochemistry | Best Researcher Award

Dr. Zu-Chian Chiang, Fujian Normal University, China.

Zu-Chian Chiang, Ph.D. 🧬 is a distinguished Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University. With a Ph.D. in Materials and Chemical Engineering from National United University, Taiwan, his research spans antibody-drug conjugates (ADCs), functional peptides, and biomaterials for cancer therapy πŸ§ͺ. He has published in reputed journals, received multiple academic awards πŸ†, and actively contributes as a peer reviewer. Dr. Chiang is dedicated to advancing translational biomedical research and cancer therapeutics πŸ’‰.

🌍 Impact and Influence

With an h-index of 5, 91 citations, and a Research Interest Score of 49.5, Dr. Chiang has made a measurable impact in biomedical sciences. His work on biomaterial scaffolds and cancer therapeutics is frequently cited in scientific literature and included in book chapters on hydroxyapatite and corticosteroid drug delivery. His publications in journals like Frontiers in Oncology, PLOS ONE, and Current Pharmaceutical Biotechnology reflect the translational value of his research.

πŸ† Awards and Honors

Dr. Chiang has been recognized multiple times for his excellence in research and service:

  • 2020 Science and Technology Commissioner, Quanzhou

  • 2017 Chairman Award, Rotary International-Taiwan

  • 2016 Biotech Elite Training Reserve Program Awardee

  • 2012 Chung Hwa Rotary Doctoral Award

  • 2010 Outstanding Doctoral Scholarship, National United University
    These honors affirm his leadership and scholarly distinction in biomedical research.

πŸš€ Legacy and Future Contributions

Beyond research, Dr. Chiang is active in academic societies and Rotary International, serving in editorial and leadership roles. As a peer reviewer, club president, and society member, he contributes to the advancement of science and community service. Looking ahead, his work on precision cancer therapies, immunoengineering, and bioactive materials positions him as a key contributor to the future of personalized medicine and biomedical innovation. πŸš€

πŸ“šPublications Top Notes

  • “Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo” (2022) πŸ§¬β€‹

    • Citations: 6​

    • Journal: Frontiers in Oncology​

    • DOI: 10.3389/fonc.2022.857927 ​

  • “Preparation and Characterization of Antibody-Drug Conjugates Acting on HER2-Positive Cancer Cells” (2020) πŸ§ͺ​

    • Journal: PLOS ONE​

    • DOI: 10.1371/journal.pone.0239813​

  • “Preparation and Characterization of Dexamethasone-Immobilized Chitosan Scaffold” (2012) πŸ—οΈβ€‹

    • Journal: Journal of Bioscience and Bioengineering​

    • DOI: 10.1016/j.jbiosc.2011.12.013​

  • “Characterization of the Morphology and Hydrophilicity of Chitosan/Caffeic Acid Hybrid Scaffolds” (2011) πŸ§«β€‹

    • Journal: Journal of Polymer Research​

    • DOI: 10.1007/s10965-011-9636-2

 

Yuan Ma | Biochemistry | Best Researcher Award

Dr. Yuan Ma | Biochemistry | Best Researcher Award

Dr. Yuan Ma, The Chinese University of Hong Kong ,China.

πŸ”¬ Dr. MA Yuan (Ph.D.) is a distinguished researcher in nucleic acid-based drug discovery and aptamer-based translational medicine. Currently a Research Assistant Professor at Hong Kong Baptist University, he has contributed extensively to targeted cancer therapies and precision medicine. With 35+ publications, multiple patents, and high-impact grants, his work advances innovative drug development. He also mentors Ph.D. and Master’s students, shaping the future of pharmaceutical sciences. His groundbreaking research continues to transform therapeutic strategies in oncology and molecular medicine. πŸ†πŸ”

🌟 Professional Profile

πŸŽ“ Early Academic Pursuits

MA Yuan’s academic journey began at the School of Pharmaceutical Sciences, Peking University, where he earned a Bachelor of Science (2009-2013), specializing in organic chemistry, pharmacology, and pharmaceutical analysis. He continued his education at the Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University, completing a Master of Science (2013-2015) with a focus on DNA synthesis, advanced medicinal chemistry, and tumor pharmacology. His Ph.D. (2015-2019) at the same institution delved into nucleic acid chemistry, advanced organic chemistry, and natural pharmaceutical chemistry, culminating in a thesis on the properties, biological activity, and mechanism of novel nucleoside (acid) lipid delivery of single-stranded oligonucleotides under the mentorship of Prof. Zhenjun Yang.

πŸ’Ό Professional Endeavors

Dr. MA Yuan’s professional career spans prestigious institutions. Since 2022, he has been a Research Assistant Professor at the Institute for Precision Medicine and Innovative Drug, Hong Kong Baptist University, leading aptamer-based translational research and drug discovery. Previously, he was a Postdoctoral Research Fellow (2020-2022) at the same institution and an Associate Research Fellow (2019-2020) at Mengchao Hepatobiliary Hospital of Fujian Medical University, where he contributed to nucleic acid-based diagnosis and treatment of primary liver cancer.

πŸ”¬ Contributions and Research Focus On BiochemistryΒ 

Dr. MA Yuan’s research primarily focuses on aptamer-based drug discovery, nucleic acid chemistry, and translational medicine. His expertise spans nucleic acid-based therapies, precision medicine, and advanced pharmaceutical formulations. He has supervised multiple postgraduate students, contributing to groundbreaking studies in triple-negative breast cancer, ovarian cancer therapy, and osteogenesis imperfecta.

🌍 Impact and Influence

Through his research, Dr. MA Yuan has secured major research grants exceeding HK$ 51 million from institutions such as the Research Grants Council and the National Natural Science Foundation of China. His work has contributed significantly to novel drug discoveries and advancements in precision medicine. He also holds three patents for innovations in nucleic acid drug delivery and targeted cancer treatments.

πŸ† Awards and Honors

Dr. MA Yuan has received several prestigious awards and recognitions, including Orphan Drug and Rare Pediatric Disease Designations from the FDA for his contributions to osteogenesis imperfecta and gastric cancer treatments.

πŸ“šAcademic Citations

Dr. MA Yuan has authored 35 peer-reviewed publications in esteemed journals, furthering knowledge in nucleic acid chemistry, aptamer-based therapies, and pharmacology. His work has been widely cited, reflecting its impact on biomedical research and pharmaceutical sciences.

  • Machine learning-powered, high-affinity modification strategies for aptamers
    Journal: Acta Materia Medica
    Year: 2025
    πŸ“šπŸ€–

  • Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
    Journal: Pharmaceutics
    Year: 2024
    πŸ’ŠπŸŽ―

  • Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics
    Journal: Journal of Medicinal Chemistry
    Year: 2024
    πŸ§¬πŸ’‰

  • Targeting osteoblastic 11Ξ²-HSD1 to combat high-fat diet-induced bone loss and obesity
    Journal: Nature Communications
    Year: 2024
    πŸ”πŸ¦΄

  • Aptamer Functionalized Hypoxia-potentiating Agent and Hypoxia-inducible Factor Inhibitor Combined with Hypoxia-activated Prodrug for Enhanced Tumor Therapy
    Journal: Cancer Letters
    Year: 2024
    Citations: Not Available
    🧬🦠

  • Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release
    Journal: Journal of Translational Medicine
    Year: 2024
    πŸŽ—οΈπŸ’ͺ

  • Sclerostin inhibition in rare bone diseases
    Journal: Journal of Orthopaedic Translation
    Year: 2024
    🦡🦴

  • Small RNAs in Cancer Therapy
    Book Chapter: Interdisciplinary Cancer Research
    Year: 2024
    Citations: Not Available
    πŸ“–πŸ§¬

  • Aptamer AS411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer
    Journal: RSC Medicinal Chemistry
    Year: 2024
    🚬πŸ’ͺ

  • Design and synthesis of nucleotidyl lipids and their application in the targeted delivery of siG12D for pancreatic cancer therapy
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    πŸπŸ”¬

  • Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential
    Journal: Molecular Therapy – Nucleic Acids
    Year: 2024
    πŸ¦΄πŸ”¬

  • The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates
    Book Chapter: Drug Metabolism and Pharmacokinetics
    Year: 2024
    πŸ’ŠπŸ§¬

  • Intracellular sclerostin plays a vital role in tumor progression and metastasis in triple-negative breast cancer
    Journal: Cancer Research
    Year: 2024
    πŸ§ πŸ”¬

  • A bimolecular modification strategy for developing long-lasting bone anabolic aptamer
    Journal: Molecular Therapy – Nucleic Acids
    Year: 2023
    🦴✨